NOV03 (Perfluorohexyloctane)

About Bausch + Lomb

Bausch + Lomb is a leading, pure-play eye health company with a mission to protect and enhance sight globally. Its strategic separation from Bausch Health in 2022 unlocked its potential to focus on the high-growth dynamics of the vision care market. The company's strength lies in its integrated portfolio across Vision Care, Pharmaceuticals, and Surgical segments, supported by significant R&D in material science and drug delivery. Its strategy is centered on innovation, geographic expansion, and leveraging its trusted brand to capitalize on powerful demographic tailwinds.

About Novaliq

Novaliq is a private, clinical-stage biotech pioneering a novel, water-free drug delivery platform (EyeSol®) for ophthalmology. Its technology is designed to enhance drug bioavailability, retention time, and tolerability on the ocular surface. The company has achieved its first commercial approvals in the US for dry eye disease (NOV03, CyclASol) and is advancing a pipeline targeting glaucoma, diabetic retinopathy, dermatology, and uveitis. With a seasoned management team and strategic partnerships, Novaliq is positioned to challenge the standard of care in topical ocular therapeutics.

Therapeutic Areas